Rubius Therapeutics, Inc.
Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof

Abstract:

The present disclosure relates to engineered erythroid cells and enucleated cells that include one or more of exogenous HLA-G polypeptides, exogenous immunogenic polypeptides, and exogenous coinhibitory polypeptides wherein the cells are capable of inducing immune tolerance and/or reducing immune response to the exogenous immunogenic polypeptides when administered to a subject.